» Articles » PMID: 34593610

MYC Hyperactivates Wnt Signaling in /-Mutated Colorectal Cancer Cells Through MiR-92a-Dependent Repression of

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2021 Oct 1
PMID 34593610
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of Wnt signaling is among the earliest events in colon cancer development. It is achieved either via activating mutations in the gene encoding β-catenin, the key transcription factor in the Wnt pathway, or most commonly by inactivating mutations affecting APC, a major β-catenin binding partner and negative regulator. However, our analysis of recent Pan Cancer Atlas data revealed that mutations significantly co-occur with those affecting Wnt receptor complex components (e.g., Frizzled and LRP6), underscoring the importance of additional regulatory events even in the presence of common / mutations. In our effort to identify non-mutational hyperactivating events, we determined that KRAS-transformed murine colonocytes overexpressing direct β-catenin target show significant upregulation of the Wnt signaling pathway and reduced expression of Dickkopf 3 (DKK3), a reported ligand for Wnt co-receptors. We demonstrate that MYC suppresses transcription through one of miR-17-92 cluster miRNAs, miR-92a. We further examined the role of DKK3 by overexpression and knockdown and discovered that DKK3 suppresses Wnt signaling in -null murine colonic organoids and human colon cancer cells despite the presence of downstream activating mutations in the Wnt pathway. Conversely, MYC overexpression in the same cell lines resulted in hyperactive Wnt signaling, acquisition of epithelial-to-mesenchymal transition markers, and enhanced migration/invasion and metastasis in a syngeneic orthotopic mouse colon cancer model. IMPLICATIONS: Our results suggest that the MYC→miR-92a-|DKK3 axis hyperactivates Wnt signaling, forming a feed-forward oncogenic loop.

Citing Articles

A novel de novo truncating variant in a Hungarian patient with CTNNB1 neurodevelopmental disorder.

Nagy N, Pal M, Nagy D, Bokor B, Zimmermann A, Gellen B BMC Pediatr. 2024; 24(1):47.

PMID: 38225558 PMC: 10789033. DOI: 10.1186/s12887-023-04509-w.


A pilot study to evaluate tissue- and plasma-based DNA driver mutations in a cohort of patients with pancreatic intraductal papillary mucinous neoplasms.

Park M, Zaw T, Yoder S, Gomez M, Genilo-Delgado M, Basinski T G3 (Bethesda). 2022; 13(2).

PMID: 36454217 PMC: 9911050. DOI: 10.1093/g3journal/jkac314.


Exosomal miR92a Promotes Cytarabine Resistance in Myelodysplastic Syndromes by Activating Wnt/β-catenin Signal Pathway.

Li H, Xie C, Lu Y, Chang K, Guan F, Li X Biomolecules. 2022; 12(10).

PMID: 36291656 PMC: 9599242. DOI: 10.3390/biom12101448.


Drug-Resistant Stem Cells: Novel Approach for Colon Cancer Therapy.

Telang N Int J Mol Sci. 2022; 23(5).

PMID: 35269660 PMC: 8910557. DOI: 10.3390/ijms23052519.

References
1.
Psathas J, Thomas-Tikhonenko A . MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med. 2014; 4(8). PMC: 4109576. DOI: 10.1101/cshperspect.a014175. View

2.
Lanauze C, Sehgal P, Hayer K, Torres-Diz M, Pippin J, Grant S . Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/β-Catenin Signaling through Enhanced Smad4-LEF1 Binding. Mol Cancer Res. 2021; 19(5):823-833. PMC: 8137583. DOI: 10.1158/1541-7786.MCR-20-0721. View

3.
Bienz M, Clevers H . Linking colorectal cancer to Wnt signaling. Cell. 2000; 103(2):311-20. DOI: 10.1016/s0092-8674(00)00122-7. View

4.
Wolfer A, Ramaswamy S . MYC and metastasis. Cancer Res. 2011; 71(6):2034-7. PMC: 3089000. DOI: 10.1158/0008-5472.CAN-10-3776. View

5.
Schee K, Boye K, Abrahamsen T, Fodstad O, Flatmark K . Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012; 12:505. PMC: 3519622. DOI: 10.1186/1471-2407-12-505. View